305 related articles for article (PubMed ID: 8123486)
1. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
2. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
3. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
4. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
5. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
Hurlimann J; Gebhard S; Gomez F
Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
[TBL] [Abstract][Full Text] [Related]
9. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
13. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
[TBL] [Abstract][Full Text] [Related]
14. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
15. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].
Ruibal A; Arias J; Del Río MC; Resino C; Tejerina A
Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137
[TBL] [Abstract][Full Text] [Related]
16. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
19. Biphasic Scatchard plots of oestrogen receptors are associated with low pS2 levels in human breast cancers.
Marsigliante S; Biscozzo L; Leo G; Storelli C
Cancer Lett; 1999 Sep; 144(1):17-23. PubMed ID: 10503873
[TBL] [Abstract][Full Text] [Related]
20. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
